Enterprise Value

5.605M

Cash

3.683M

Avg Qtr Burn

-6.249M

Short % of Float

8.22%

Insider Ownership

28.01%

Institutional Own.

5.83%

Qtr Updated

01/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

TAVO™-EP + pembrolizumab Details
Melanoma, Non-small cell lung carcinoma, Thermal burns, Rhabdomyosarcoma, Cancer

Phase 2

Initiation

CORVax12 (TAVO + SARS-CoV-2 spike glycoprotein) Details
COVID-19, Hepatitis B vaccine, Hepatitis B

Failed

Discontinued

TAVO™-EP + epacadostat + pembrolizumab Details
Cancer, Head and neck cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

TAVO™-EP + pembrolizumab Details
Breast cancer, Triple-negative breast cancer

Failed

Discontinued